Patient-reported outcomes (PROs) for patients with myelofibrosis (MF) have been well
characterized, but little is known about quality of life (QoL) following allogeneic stem cell …

Abstract Introduction Myelofibrosis (MF) and Post PV/ET MF represents a group of
debilitating hematological disorders in which quality of life (QOL) is severely compromised in …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …

Hematopoietic stem cell transplantation (HCT) is a curative treatment for patients with
myelofibrosis (MF); however, many HCT-eligible patients decline this potentially life-saving …

Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic
hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed …

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in
myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to …

Allogeneic hematopoieteic stem cell transplantation (HSCT) is the only curative treatment for
myelofibrosis (MF), but it is still associated with significant risks and complications. One of …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe
constitutional symptoms (ie fatigue, night sweats, fever, weight loss), pruritus, and symptoms …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …